Multi-species synbiotic vs. placebo for bloating, gas, and abdominal discomfort: a 6-week randomized controlled trial
Six weeks of multi-species synbiotic supplementation (24 strains + pomegranate extract) significantly improved digestive quality of life, bloating/gas, and abdominal pain scores versus placebo in generally healthy adults with chronic complaints.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Digestive quality of life (DQLQ) | B | ▲ Favorable | p<0.05 vs placebo; IC 95% NR | 1 |
| Bloating and gas (PROMIS-GI 13a) | B | ▲ Favorable | p<0.05 vs placebo; IC 95% NR | 1 |
| Abdominal pain/discomfort (PROMIS-GI 5a) | B | ▲ Favorable | p<0.05 vs placebo; IC 95% NR | 1 |
| Constipation | C | ▲ Favorable | Likert 5-pt; IC 95% NR | 1 |
| Anxiety (PROMIS-Anxiety 4a) | C | — Insufficient | IC 95% NR; direção não confirmada no extrato | 1 |
| Safety (adverse events) | B | — Neutral | Sem eventos adversos graves atribuídos; IC 95% NR | 1 |
Context
Bloating affects approximately 1 in 7 Americans weekly and impairs quality of life. Prior single- or dual-strain probiotic trials in healthy individuals failed to show benefit for bloating and gas. This trial tests whether a 24-strain synbiotic with polyphenolic prebiotic changes that outcome.
What the study showed
The synbiotic group showed statistically significant improvement in DQLQ score (digestive quality of life) versus placebo at week 6 (direction: favors synbiotic; absolute values and 95% CI not explicitly reported in available text). PROMIS-GI bloating/gas and abdominal pain/discomfort scores also improved significantly in the active versus placebo group. No serious adverse events were attributed to the synbiotic. Effect sizes were expressed as score differences on validated instruments, not as absolute event counts.
How it was done
Randomized, double-blind, placebo-controlled, parallel-group, decentralized (online) trial conducted in the USA over 6 weeks. Participants recruited via social media and email lists; 1:1 randomization. Of 622 screened, 350 enrolled at baseline and 219 completed week-6 assessment (~37% attrition).
Effect magnitude
Specific effect sizes (SMD, MD, RR, OR with 95% CI) were not extractable from the available full text; authors report statistical significance (p<0.05) for primary and key secondary endpoints, with the trial powered at 90% for n=210 evaluable participants.
Limitations
~37% attrition (350→219) with potential unadjusted attrition bias; intention-to-treat analysis not confirmed in the available extract. Online self-selected recruitment limits representativeness. No objective measures (e.g., hydrogen breath test, manometry). Six-week duration precludes conclusions on durability of effects. Potential conflict of interest: product is marketed by Seed Health, Inc. RoB 2 tool not applied by authors.
In clinical practice
In generally healthy adults with chronic bloating and no medical diagnosis, this 24-strain synbiotic with polyphenolic prebiotic showed reduced bloating, gas, and abdominal discomfort scores over 6 weeks. Clinicians should weigh the incompletely quantified effect size against cost, high study attrition, and potential sponsor conflict of interest. This study provides no basis for recommending the product in IBS or other diagnosed GI conditions.
What is still missing
Trials with ≥6-month follow-up, rigorous intention-to-treat analysis, objective measures of intestinal fermentation, and independent (non-industry-funded) replication are needed to consolidate the evidence.